Mylan surges, Teva slumps after FDA approves Copaxone copy

(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news